News & Topics Past News
2019.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Directors
2019.04.22
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company's Employees
2019.04.18
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.17
Analyst Report[Corporate outlook] (EDISON)
2019.04.16
Analyst Report[Basic Report] (Fair Research)
2019.04.12
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.10
Notice of the Large Volume Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.10
First patient enrolled in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
2019.04.08
Completion of Patient Enrollment in the Phase 3 Clinical Trial of the Anti-cancer Drug TREAKISYM for the Indication of relapsed/refractory diffuse large B-cell lymphoma
2019.04.03
Analyst Report[Full report] (Shared Research)
2019.04.01
Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.04.01
Onconova Announces Over 75 Percent of Planned Enrollment Achieved in Phase 3 INSPIRE Study of Rigosertib
2019.03.29
Notice of Shareholder Voting Results for the 14th Ordinary General Meeting of Shareholders
2019.03.28
Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
2019.03.28
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2019.03.28
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2019.03.28
Notice of Board of Director, Audit & Supervisory Board, and Corporate Officer Appointments
2019.03.26
TREAKISYM Approved for use as a Pretreatment to Adoptive T-Cell Therapy
2019.03.14
Notice of Instruction for Front-Loading Exercise of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2019.03.11
Information on Shareholders' Meeting: Updated the Page
2019.03.05
(Correction Notice of Press Release) Notice Regarding Reverse Stock Split and Amendment to the Articles of Incorporation
2019.02.28
Notice Regarding Reverse Stock Split and Partial Amendment to Articles of Incorporation
2019.02.28
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2019.02.07
SymBio's Mid-Range Plan: FY 2019 to FY 2022 (Four Years)
2019.02.07
Notice Concerning Non-operating Expenses
2019.02.07
Summary of Financial Statements for the Fiscal Year Ended December 31, 2018[Japanese GAAP] (Non-consolidated)
2019.01.07
Onconova Announces Submission of Special Protocol Assessment (SPA) to FDA for Phase 3 Trial of Oral Rigosertib
2018.12.20
Shipments of the 25mg Presentation of Anti-cancer Drug TREAKISYM Intravenous Infusion Paused and Shipment of Substitute
2018.12.17
Completion of Exercise of the 39th Stock Acquisition Rights Issued by way of Third Party Allotment
2018.12.12
Analyst Report[Strategy update](EDISON)
2018.12.07
Analyst Report[Full report] (Shared Research)
2018.12.04
Onconova Presents Results from Phase 2 Trial of Oral Rigosertib in Myelodysplastic Syndromes (MDS) at the ASH 2018 Meeting
2018.11.30
Clinical Trial Begins for TREAKISYM Liquid Formulation(Rapid Infusion Injection Formulation)